We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Please provide feedback for this on the following(scale 1-5, 1 strongly disagree; 5 strongly agree):
* = Mandatory Field
Here at Touch Medical Media, we are supporting World Cancer Day (4 February 2023) in the second year of the three-year campaign called ‘Close the Care Gap’. In 2022, the theme was all about ‘Realizing the problem’. This year, the focus is on ‘Uniting our voices and taking action’. “In recognition of World Cancer Day’s […]
touchREVIEWS in Oncology & Haematology. 2023;19(1): Online ahead of journal publication
Human epidermal growth factor receptor-2 (HER2)-positive breast cancer accounts for 15% of all breast cancers.1 This breast cancer subtype was historically associated with poor outcomes; however, the development of HER2-directed therapies has dramatically improved outcomes for patients with both early and advanced HER2+ disease.2 Currently, there are several types of HER2-targeted agents approved for the […]
“If you want something you never had, you have to do something you’ve never done.” So, reputedly, said a Mr Thomas Jefferson, in a different age and in a different place, but the advice remains timeless. The quotation comes to our mind as, at the time of writing, we reflect at the end of the […]
touchREVIEWS in Oncology & Haematology. 2023;19(1):Online ahead of journal publication
Paediatric low-grade gliomas (pLGGs) most commonly develop in the cerebellum and can be resected safely, with minimal neurological complications and long-term cure achieved following surgery alone.1 However, a large proportion of pLGGs that develop in other parts of the brain remain unresectable and ultimately manifest as a chronic disease.2 The most common location at which unresectable pLGG […]
touchREVIEWS in Oncology & Haematology. 2022;19(1):Online ahead of journal publication
In recent years, our understanding of the complement system and its role in disease has increased dramatically. With the advent of complement 5 (C5) and C3 inhibitors, our ability to manipulate the complement system has improved the outcomes and quality of life for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic–uraemic syndrome.1–3 More recently, this understanding […]
touchREVIEWS in Oncology & Haematology. 2022;18(2):113–9
Bladder cancer (BC) is the sixth most common cancer in the world, accounting for 81,180 estimated new cases and 17,100 deaths in 2022.1 BC is most frequently diagnosed among people aged 65–74 years.1 For patients with disease limited to the bladder, the depth of invasion of the primary tumour is the most important prognostic variable in […]
touchREVIEWS in Oncology & Hameatology. 2022;18(2):96-7 DOI: https://doi.org/10.17925/OHR.2022.18.2.96
The optimal maintenance approach postautologous stem cell transplantation (ASCT) for patients with multiple myeloma is still an area of ongoing research. Lenalidomide has demonstrated clear superiority in clinical trials compared to placebo, and continuous post-transplant lenalidomide until progression is considered standard of care. All patients, however, do not derive equal benefit from single-agent lenalidomide, and […]
Welcome to the latest edition of touchREVIEWS in Oncology & Haematology, which features a wealth of topical and practical content for oncologists and haematologists, as well as being of interest to the wider medical community. We open with an editorial by Joseph Franz and Sagar Lonial, looking at the potential of the ATLAS trial (ClinicalTrials.gov Identifier: […]
touchREVIEWS in Oncology & Haematology. 2022;18(2):125-9 DOI: https://doi.org/10.17925/OHR.2022.18.2.125
Head and neck squamous cell carcinomas (HNSCCs) encompass a diverse group of tumours arising from the nasopharynx, oral cavity, oropharynx, hypopharynx and larynx. Tobacco and alcohol abuse are risk factors for the development of HNSCC, particularly oral cavity, hypopharyngeal and laryngeal cancers, whereas Epstein–Barr virus (EBV) and human papillomavirus (HPV) can mediate tumourigenesis in nasopharyngeal […]
Get the latest clinical insights from touchONCOLOGY